Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Bernd Brust, Michael Hunkapiller, Hugh Martin, Daniel Grosu, and Patrice Milos

Premium

Bernd Brust has resigned as president of molecular medicine at Life Technologies.

Brust will continue to serve as a consultant to the company for two months ending Dec. 31, according to documents filed with the US Securities and Exchange Commission. He will receive $5,000 per month, continued vesting of his outstanding equity awards, and health benefits during the consulting period, and nine months of outplacement assistance.

Previously, Brust served as president of commercial operations at Life Tech and senior vice president of global sales at Invitrogen. He has also held various roles at GE Medical Systems Information Technologies. He holds a degree in engineering from MTS in Amsterdam.



Pacific Biosciences
has appointed Michael Hunkapiller as executive chairman of its board of directors, which the company announced during a conference call to discuss its third-quarter results (see story, this issue). Hugh Martin will continue to serve as president and CEO.

Hunkapiller has served on the board of directors since 2005. He is a general partner at Alloy Ventures and former president and general manager of Applied Biosystems, which he co-founded. He was also a founder of Celera Genomics and senior vice president of Applera.

He holds a BS in chemistry from Oklahoma Baptist University and a PhD in chemical biology from California Institute of Technology.


Illumina has named Daniel Grosu as vice president and chief medical officer, a newly created position. In this role, Grosu will help build Illumina's diagnostic capabilities through collaborations with regulatory agencies, internal product development teams, and the company's CLIA-certified clinical laboratory.

Previously, Grosu was group director of clinical science and clinical and medical affairs at Ortho-Clinical Diagnostics. He has also served as director and global clinical leader of global clinical development and diagnostic imaging at Bayer Healthcare. He holds a BS and an MS from Wheaton College, an MD from Saint Louis University, and an MBA from the University of Oxford.


Patrice Milos has left Helicos BioSciences, where she was vice president and chief scientific officer, to become Boston site head and precision medicine lead for Pfizer's Centers for Therapeutic Innovation. She remains a senior scientific advisor for Helicos.

Milos joined Helicos in 2007 from Pfizer Global Research and Development, where she was executive director. She holds PhD and MS degrees from Rensselaer Polytechnic Institute and a BA from the College of Saint Rose.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.